SUMMARY -Infl ammation plays an important role in the initiation and progression of peripheral artery disease (PAD). Patients with diabetes have an increased risk of developing PAD. Data regarding the prognostic implication of diabetes and infl ammation in PAD patients are scarce. Th e aim of the study was to investigate the impact of diabetes and infl ammation on all-cause mortality in patients with symptomatic PAD and preserved left ventricular ejection fraction (LVEF >50%). Th e study was conducted at the Sestre milosrdnice University Hospital Center between January 2010 and January 2014 on 319 consecutive patients with symptomatic PAD and preserved LVEF (66.5% men, mean age 70±10 years, ankle brachial index 0.58±0.14). Th irty-eight (12%) patients died during median follow up period of 24 months (interquartile range, 16-34 months). On univariate analysis, C-reactive protein was signifi cantly associated with all-cause mortality (HR 2.21, 95% CI 1.09-4.48). After multivariate regression analysis, age (HR 1.07, 95% CI 1.02-1.11), diabetes (HR 2.24, 95% CI 1.04-4.82), and critical limb ischemia (HR 2.22, 95% CI 1.03-4.80) remained the only independent predictors for all-cause mortality. Diabetes and critical limb ischemia are independently associated with an increased risk of mortality in symptomatic PAD patients with preserved LVEF.
Introduction
Peripheral artery disease (PAD) is a multifactorial syndrome that is associated with a very high risk of ischemic events, namely myocardial infarction, stroke, and death 1 . Th e probability of having polyvascular disease is greater in patients with PAD, indicating an extensive and severe degree of systemic atherosclerosis. Th ese patients, despite more intense medical therapy, have poorer control of modifi able risk factors and higher mortality rate 2, 3 .
Patients with diabetes mellitus have a 2-to 4-fold higher risk of developing PAD 4, 5 . Progression of atherosclerosis, as well as poor outcomes, are more often present in diabetic PAD patients, probably because of the abnormal metabolic state and increase in vascular infl ammation 6 . PAD has been identifi ed as a risk factor for glycemic dysregulation in type 2 diabetes mellitus 7 . Prospective clinical trials have shown that the occurrence of major adverse cardiovascular events (MACE) and all-cause mortality is higher in patients with both diabetes and PAD than in nondiabetic PAD patients [8] [9] [10] . C-reactive protein (CRP) has been established as a risk factor for the development of type 2 diabetes and cardiovascular disease, including PAD 11, 12 . Elevated CRP levels are present in patients with impaired glucose tolerance and are associated with the stage of be-ta-cell dysfunction and insulin resistance 13 . Results from the West of Scotland Coronary Prevention Study have shown that CRP concentration is a signifi cant predictor of diabetes in middle-aged men, independent of the risk factors such as body mass index, fasting triglycerides and glucose levels 14 . Th e predictive role of CRP has been well studied in acute coronary and acute aortic syndromes 15, 16 . We have recently shown that CRP independently predicted MACE in patients with symptomatic PAD and preserved left ventricular systolic function 17 . Patients with PAD have a higher prevalence of diabetes and higher levels of infl ammatory biomarkers compared to patients without PAD 18 . Th erefore, the aim of the study was to investigate the role of diabetes and infl ammation for all-cause mortality in patients with symptomatic PAD and normal left ventricular ejection fraction (LVEF).
Patients and Methods
Th e study population consisted of 319 consecutive patients with symptomatic PAD and preserved LVEF admitted to the Sestre milosrdnice University Hospital Center between January 2010 and January 2014. Fiftyfi ve patients were excluded due to LVEF <50% (n=39), malignancy (n=12) and concomitant autoimmune disorders (n=4). During hospital stay, demographic data and clinical characteristics of the patients were recorded and included general information (age, sex, weight and height), data on cardiovascular risk factors, biochemical and hematological laboratory data, comorbidities, and medications. Renal function was assessed by estimating the glomerular fi ltration rate (eGFR) using the Modification of Diet in Renal Disease formula 19 . LVEF was assessed using transthoracic echocardiography (Simpson's method), and only patients with preserved LV systolic function (LVEF >50%) were included in the study. Baseline anemia was defi ned according to the World Health Organization criteria (hemoglobin level <13 g/ dL for men and <12 g/dL for women) 20 . Th e diagnosis of PAD was established by clinical examination, ankle brachial index (ABI) measurement, duplex sonography and/or computed tomography or magnetic resonance angiography, and confi rmed with peripheral angiography using the criteria of the Euro- 24 . Cardiovascular disease, in addition to confi rmed PAD, was defi ned as history of angina, myocardial infarction, coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting), history of stroke, transient ischemic attack, or carotid revascularization.
High sensitivity CRP was determined on admission by immunoturbidimetric method (Olympus, Dublin, Ireland).
Study endpoint was the all-cause mortality. Mortality was documented by death certifi cates or by reviewing hospital records. Th e median follow up was 24 months (interquartile range 16-34 months). Outcome was assessed by independent observers blinded to patient laboratory and clinical data. Th e investigation was performed in accordance with the Declaration of Helsinki and was approved by the University Hospital Center Ethics Committee.
Continuous normally distributed variables were expressed as mean (± standard deviation) and non-normally distributed variables as medians (interquartile range). Diff erences between the groups were analyzed with t-test and Mann-Whitney test for continuous variables and with c 2 -test for categorical variables. Normality of distribution was tested with KolmogorovSmirnov test. Th e ability of CRP to predict mortality was tested by the receiver-operating characteristic (ROC) analysis and optimal cut-off point of CRP was dichotomized to > or <4.5 mg/L. Kaplan-Meier analyses with log-rank test were performed and comparisons were based on the presence of diabetes and CLI. Cox proportional-hazards regression analysis was performed to determine the independent predictors of all-cause mortality and results were expressed as hazard ratios (HR) and 95% confi dence intervals (CI). Covariate selection included known correlates of poor cardiovascu-lar outcome and those that were found to be signifi cant on univariate analysis, i.e. age, gender, CLI, anemia, renal function, CRP and diabetes. Th e value of p<0.05 was considered statistically signifi cant. Statistical analysis was performed using the MedCalc® Version 11.3.1.0 (MedCalc, Ostend, Belgium).
Results
Baseline characteristics of the study population are shown in Table 1 . Of 319 symptomatic PAD patients with preserved LVEF, 172 (54%) had type 2 diabetes. (Table 2) . CLI and diabetes predicted freedom from all-cause mortality, and patients having both CLI and diabetes were 6.6 times (95% CI 2.89-14.99) more likely to die than those with claudication but without diabetes (Fig. 1A, 1B, and 1C) . After multivariable analysis, age, diabetes and CLI remained the only independent predictors of mortality (Table 2) .
Discussion
Th e present study investigated the prognostic role of diabetes and infl ammation for all-cause mortality in patients with symptomatic PAD and preserved LVEF. Age, diabetes, and CLI were found to be the only independent predictors of all-cause mortality in the study population.
Previous epidemiological studies showed a higher incidence of PAD in diabetic patients. Furthermore, patients with both PAD and diabetes have more often CLI, a higher prevalence of amputation and greater risk of mortality 25 . Our study showed the patients with symptomatic PAD and diabetes to be at more than twofold greater risk of death compared with non-diabetic PAD patients. Th is is in line with Leibson et al. 26 , who showed that the adjusted risk of all-cause mortality in patients with both PAD and diabetes was 2.2 times higher than for patients with PAD alone. Golledge et al. 27 investigated patients with occlusive or aneurysmal disease of peripheral arteries and showed 1.6-to 1.7-fold and 2.0-to 2.9-fold higher mortality risk in patients with non-medicated diabetes and patients with diabetes receiving insulin, respectively, as compared with non-diabetics.
Critical limb ischemia is the most severe form of PAD with poor overall survival. Th e annual mortality rate in patients with CLI is approximately 25% and between 50% and 70% at 5 years 28 . Lower ABI values and diabetes are the most important risk factors for the development of CLI 29 . Vogt et al. 30 have reported that patients with ABI <0.5 have a higher relative risk of all-cause mortality compared to patients with higher ABI values. In our study, patients with CLI had two times increased risk of all-cause mortality compared to patients without CLI.
C-reactive protein is a regularly used biomarker in daily clinical practice, and of note, patients with diabetes have increased levels of infl ammatory biomarkers, such as CRP 8 . Data on the prognostic role of CRP for all-cause mortality in PAD patients are controversial. It has been shown that in patients with symptomatic PAD, increased CRP values are independently associated with all-cause mortality within 2 years, but at longer follow up period, the biomarker lost its prognostic signifi cance 31 . CRP is associated with the development and severity of PAD, as well as of impaired glucose regulation 12 . Moreover, in patients with PAD, elevated 33 have reported that CRP and CLI were independent predictors of death among patients with symptomatic PAD. Our study clearly revealed that CRP was signifi cantly associated with all-cause mortality on the univariate but not after multivariate analysis.
Although anemia was found to be an independent predictor of composite outcome (death and limb amputation) in patients hospitalized for PAD, it was not included in the earlier outcome studies 34 . We have to bear in mind that patients with chronic kidney disease have an increased risk of developing PAD, and renal impairment was found to predict all-cause mortality in patients with symptomatic PAD 35, 36 . Left ventricular systolic dysfunction is quite prevalent in PAD patients and is associated with all-cause mortality 37 . So, we believe this is the fi rst report that showed the independent prognostic role of diabetes and CLI for mortality in symptomatic PAD patients with preserved left ventricular systolic function, regardless of renal function, anemia and infl ammation.
Patients with PAD are at an increased risk of MACE and all-cause mortality compared to general population. Additionally, lower ABI values correlated with reduced survival and increased rate of concomitant coronary and cerebrovascular disease 38 . Despite a very high incidence of MACE and mortality rate, PAD is still underdiagnosed and undertreated. Th erefore, screening for PAD, early management, together with modifi cation of cardiovascular risk factors and timely assessment of prognosticators for unfavorable outcome are of utmost importance.
In conclusion, our data confi rm that diabetes and CLI are independent predictors for all-cause mortality in patients with symptomatic PAD and preserved LVEF. Additionally, the coexistence of CLI and diabetes signifi cantly increased the risk of worse clinical outcome. 
